Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors

Journal of Pediatric Hematology/Oncology

Volumn 18, Issue 1, 1996, Pages 13-22

  Kadota, Richard P ^a,b  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b MC 5035 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; GAMMA INTERFERON; GYRASE INHIBITOR; IDARUBICIN; IFOSFAMIDE; INTERLEUKIN 2; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BIOLOGICAL THERAPY; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHILD; CHILDHOOD CANCER; DOSE RESPONSE; DRUG SCREENING; HEMATOPOIETIC STEM CELL; HUMAN; MEDULLOBLASTOMA; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT; INTERFERONS; INTERLEUKIN-2;

EID: 0030071018     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199602000-00004     Document Type: Review

References (110)

1. Evans AE, Jenkin RDT, Sposto R, et al. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572-82.
2. Tait DM, Thornton-Jones H, Bloom HJG, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464-9.
3. Krischer JP, Ragab AH, Kun L, et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991;74:905-9.
4. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993; 328:1725-31.
5. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in one day: a report from the Children's Cancer Group. J Clin Oncol 1994;12:1606-15.
6. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice updates. Philadelphia: Lippincott, 1988:121-42.
7. Cheung N-K, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9:1050-8.
8. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-70.
9. Frei E III, Antman K, Teicher B, et al. Bone marrow autotransplantation for solid tumors - prospects. J Clin Oncol 1989;7:515-26.
10. Friedman HS, Oakes WJ. The chemotherapy of posterior fossa tumors in childhood. J Neurooncol 1987;5:217-9.
11. Allen JC, Helson L. High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981;55:749-56.
12. Castello MA, Clerico A, Deb G, et al. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 1990;12:297-300.
13. Abrahamsen TG, Lange B, Packer R, et al. High-dose cyclophosphamide with granulocyte/macrophage colony-stimulating factor (GM-CSF) in malignant brain tumors in children [Abstract]. Med Pediatr Oncol 1992;20:381.
14. LaChance DH, Oette D, Schold SC, et al. Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system neoplasms. Med Pediatr Oncol 1995;24:241-7.
15. Kalifa C, Hartmann O, Demeocq F, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992;9:227-33.
16. Kalifa C, Hartmann O, Vassal G, et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation as a salvage therapy for non irradiated medulloblastoma patients [Abstract]. Proc Am Soc Clin Oncol 1993;12:425.
17. Kalifa C, Hartmann O, Doz F, et al. Post radiation high dose busulfan and thiotepa with autologous bone marrow transplant in malignant brain stem glioma [Abstract]. Med Pediatr Oncol 1992;20:414.
18. Finlay JL. High-dose chemotherapy and autologous marrow rescue for malignant brain tumors [Abstract]. Pediatr Neurosurg 1994;21:158-9.
19. Dunkel I, Garvin J, Goldman S, et al. High-dose chemotherapy with autologous bone marrow rescue does not cure children with brain stem tumors [Abstract]. Pediatr Neurosurg 1994;21:219.
20. Heideman RL, Douglass EC, Krance RA, et al. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. J Clin Oncol 1993;11:1458-65.
21. Mahoney D, Strother D, Bowen T, et al. High dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a phase I-II Pediatric Oncology Group study [Abstract]. Proc Am Soc Clin Oncol 1994;13:174.
22. Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy. J Clin Oncol 1994;12:28-36.
23. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
24. Shapiro WR. Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol 1992;148:428-34.
25. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-82.
26. Groothuis DR, Warkne PC, Molnar P, et al. Effect of hyperosomotic blood-brain disruption on transcapillary transport in canine brain tumors. J Neurosurg 1990;72:441-9.
27. Friedman HS, Ochs J, Finlay J, et al. Phase I trial of intrathecal 4-hydroperoxycyclophosphamide for neoplastic meningitis [Abstract]. Proc Am Assoc Cancer Res 1993;34:269.
28. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology, ed 2. Philadelphia: JB Lippincott, 1993;197-246.
29. Tomita T. Interstitial chemotherapy for brain tumors: review. J Neurooncol 1991;10:57-74.
30. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441-6.
31. Brem H, Piantadosi S, Burger PC, et al. Intraoperative chemotherapy using biodegradable polymers: safety and effectiveness for recurrent glioma evaluated by a prospective multi-institutional placebo-controlled clinical trial [Abstract]. Proc Am Soc Clin Oncol 1994;13:174.
32. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors. J Neurooncol 1994;20:121-39.
33. Phillips PC. Antineoplastic drug resistance in brain tumors. Neurol Clin 1991;9:383-404.
34. Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors. J Neurooncol 1994;20:165-76.
35. Becker I, Becker KF, Meyermann R, et al. The multidrug-resistance gene MDR1 is expressed in human glial tumors. Acta Neuropathol 1991;82:516-9.
36. Matsumoto T, Tani E, Kaba K, et al. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 1991;74:460-6.
37. Henson JW, Cordon-Cardo C, Posner JB. P-glycoprotein expression in brain tumors. J Neurooncol 1992;14:37-43.
38. Tishler DM, Weinberg KI, Sender LS, et al. Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. J Neurosurg 1992;76:507-12.
39. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
40. Nabors MW, Griffin CA, Zehnbauer BA, et al. Multidrug resistance gene (MDR1) expression in human brain tumors. J Neurosurg 1991;75:941-6.
41. Tishler DM, Raffel C. Development of multidrug resistance in a primitive neuroectodermal tumor cell line. J Neurosurg 1992;76:502-6.
42. Kiwit JC, Hertel A, Matuschek AE. Reversal of chemoresistance in malignant gliomas by calcium antagonists. J Neurosurg 1994;81:587-94.
43. Russo A, Charmichael J, Friedman N, et al. The roles of intracellular glutathione in antineoplastic chemotherapy. Int J Radiat Oncol Biol Phys 1986;12:1347-54.
44. Bailey HH, Mulcahy RT, Tutsch KD, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994;12:194-205.
45. 6 alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989;70:573-7.
46. Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992;84:1926-31.
47. 6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines. Cancer Res 1992;52:1144-1148.
48. Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors: a Children's Cancer Study Group phase II trial. Cancer 1990;66:2465-9.
49. Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992;10:249-56.
50. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low grade gliomas of childhood. J Clin Oncol 1993;11:850-6.
51. Cohen ME, Mahoney DH, Duffner PK, et al. Evaluation of optic pathway tumors: natural history and treatment. Pediatric Oncology Group study preliminary report [Abstract]. Ann Neurol 1994;36:505.
52. Chastagner P, Sommelet-Olive D, Kalifa C, et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology. Med Pediatr Oncol 1993;21:49-53.
53. Heideman RL, Packer RJ, Reaman GH, et al. A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Cancer 1993;72:271-5.
54. Reid JM, Pendergrass TW, Krailo MD, et al. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 1990;50:6525-8.
55. Schott B, Robert J. Comparative cytotoxicity. DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol 1989;38:167-72.
56. Chabner BA. Taxol. PPO Updates 1991;9:1-10.
57. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992;52:3495-7.
58. Hei TK, Hall EJ. Taxol, radiation, and oncogenic transformation. Cancer Res 1993;53:1368-2.
59. Walter KA, Cahan M, Brem H. Taxol's effectiveness against malignant brain tumor cell lines in vitro [Abstract]. Proc Am Assoc Cancer Res 1993;34:383.
60. Rowinsky EK, Chaudhry V, Cornblath DR, et al. Neurotoxicity of taxol. Monogr Natl Cancer Inst 1993;15:107-15.
61. Burris HA III, Fields SM. Topoisomerase I inhibitors. Hematol/Oncol Clin North Am 1994;8:333-55.
62. Friedman HS, Houghton PJ, Schold SC JR, et al. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against CNS xenografts [Abstract]. Proc Am Assoc Cancer Res 1993;34:422.
63. Vassal G, Morizet J, Bissery M-C, et al. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenografts [Abstract]. Pediatr Neurosurg 1994;21:162-3.
64. Eisenhauer EA, Wainman N, Boos G, et al. Phase II trials of topotecan in patients with malignant glioma and soft tissue sarcoma [Abstract]. Proc Am Soc Clin Oncol 1994;13:175.
65. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 1993;29A:940-2.
66. Mahaley MS Jr, Urso MB, Whaley RA, et al. Immunobiology of primary intracranial tumors. J Neurosurg 1985;63:719-25.
67. Nagai M. Clinical use of interferons in the treatment of malignant brain tumors. In: Revel M, ed. Clinical aspects of interferons. Boston: Kluwer, 1988:183-94.
68. Yung WKA, Prados M, Levin VA, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991;9:1945-9.
69. Allen J, Packer R, Bleyer A, et al. Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:738-88.
70. Mahaley MS Jr, Bertsch L, Cush S, et al. Systemic gamma-interferon therapy for recurrent gliomas. J Neurosurg 1988;69:826-9.
71. Saris SC, Rosenberg SA, Friedman RB, et al. Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. J Neurosurg 1988;69:29-34.
72. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992;10:180-99.
73. Merchant RE, McVicar DW, Merchant LH, et al. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha: results of a phase I clinical trial. J Neurooncol 1992;12:75-83.
74. Topalian SL, Rosenberg SA. Adoptive cellular therapy: basic principles. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:178-96.
75. Hayes RL. The cellular immunotherapy of primary brain tumors. Rev Neurol 1992;148:454-66.
76. Allen J, Hayes R, DaRosso R, et al. Intraventricular interleukin-2 (IL-2) lymphokine activated killer (LAK) cells for leptomeningeal metastases (LM) in pediatric brain tumors [Abstract]. Proc Am Soc Clin Oncol 1993;12:528.
77. Jaeckle KA. Immunotherapy of malignant gliomas. Semin Oncol 1994;21:249-59.
78. Saris SC, Spiess P, Lieberman DM, et al. Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 1992;76:513-9.
79. Tada M, de Tribolet N. Recent advances in immunobiology of brain tumors. J Neurooncol 1993;17:261-71.
80. Grossbard ML, Press OW, Appelbaum FR, et al. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992;80:863-78.
81. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993;14:252-9.
82. Vallera DA. Immunotoxins: will their clinical promise be fulfilled? Blood 1994;83:309-17.
83. Packer RJ, Kramer ED, Ryan JA. Biologic and immune modulating agents in the treatment of childhood brain tumors. Neurol Clin 1991;9:405-22.
84. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg 1992;76:1-12.
85. Stavrou D, Bise K, Groeneveld J, et al. Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies. Anticancer Res 1989;9:1489-96.
86. Schuster JM, Bigner DD. Immunotherapy and monoclonal antibody therapies. Curr Opin Oncol 1992;4:547-52.
87. Colombatti M, Dipasquale B, Del-L'Arciprete L, et al. Heterogeneity and modulation of tumor-associated antigens in human glioblastoma cell lines. J Neurosurg 1989;71:388-97.
88. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytoma treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992;22:225-30.
89. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas. Cancer 1994;73:1076-82.
90. Moseley RP, Davies AG, Richardson RB, et al. Intrathecal administration of 131I radiolabeled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer 1990;62:637-42.
91. Friedman, HS, Oakes WJ. New therapeutic options in the management of childhood brain tumors. Oncology 1992;6:27-40.
92. Nitta T, Sato K, Yagita H, et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335:368-71.
93. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 1990;87:4207-11.
94. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994;344:82-6.
95. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-32.
96. Deisseroth AB. Current trends and future directions in the genetic therapy of human neoplastic disease. Cancer 1993;72:2069-74.
97. Greenberg SJ. Advances in molecular genetic treatment of cancer. In: Cohen ME, Duffner PK, eds. Brain tumors in children, ed 2. New York: Raven, 1994:147-60.
98. Gilboa E, Lyerly HK. Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biol Ther Cancer 1994;4:1-16.
99. Yung WKA, Taylor S, Steck PA. Modulation of EGFR/TGF-a autocrine growth regulation in human glioma by antisense approaches - potential agents for molecular therapy [Abstract]. J Neurooncol 1993;15:S30.
100. Trojan J, Johnson TR, Rudin SD, et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. Science 1993;259:94-7.
101. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
102. Badie B, Black KL. Intratumoral injection of p53 gene using adenoviral vector inhibits 9L glioma growth in rats [Abstract]. Neurosurgery 1994;35:576.
103. Aka K, Bruner JM, Bondy ML, et al. Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. J Neurooncol 1993;16:125-33.
104. Chozick BS, Weicker ME, Pezzullo JC, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 1994;73:406-15.
105. Litofsky NS, Hinton D, Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994;34:967-72.
106. Yu JS, Wei MX, Chiocca EA, et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993;53:3125-8.
107. Heslop HE. Cytokine gene transfer in the therapy of malignancy. Bailliere's Clin Haematol 1994;7:135-51.
108. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin-7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992;89:3850-4.
109. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
110. Randall T. Gene therapy for brain tumors in trials, correction of inherited disorders a hope. JAMA 1993;269:2181-2.